A Lancet Diabetes & Endocrinology consensus statement highlights nutrition, muscle, function, GI symptoms, and psychological support during incretin therapy.
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
